Can-Fite BioPharma has submitted a paediatric study plan to the US Food and Drug Administration (FDA) for treating adolescents with psoriasis using its anti-inflammatory drug Piclidenoson.

Due to Piclidenoson’s favourable safety profile, FDA allowed Can-Fite to enrol adolescents with psoriasis and include them in its two Phase III pivotal clinical studies.

The inclusion of adolescent patients in one or both Phase III studies is believed to significantly broaden any future market launch potential of Piclidenoson.

The data from these trials will be further used by Can-Fite to register the drug with both the FDA and the European Medicines Agency to treat plaque psoriasis.

Can-Fite BioPharma CEO and CFO Motti Farbstein said: “Based on the FDA’s recommendation to enrol adolescents into the upcoming Phase III psoriasis trials, we believe Piclidenoson’s oral formulation with an excellent safety record, combined with its progressive effectiveness over time, make it ideally suited for the chronic treatment of psoriasis in adults and adolescents alike.”

Earlier, favourable results of Piclidenoson were observed in the Phase III placebo- and active-controlled, double-blind, multicentre, randomised COMFORT study for psoriasis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study met its primary endpoint with statistically significant improvement compared with placebo, as measured by the Psoriasis Area and Severity Index (PASI) 75 response.

Can-Fite’s cancer and liver drug Namodenoson is also being assessed in a Phase IIb trial to treat non-alcoholic steatohepatitis.

The company is also planning to initiate a Phase III trial for hepatocellular carcinoma and a Phase IIa study in pancreatic cancer.